• Explore /
  • Poster
  • / Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).

Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).

Abstract Poster

Authors

null

Tamim Niazi

Jewish General Hospital, McGill University, Montréal, QC, Canada

Tamim Niazi , Paul L. Nguyen , Scott Williams , Martin R. Stockler , Andrew James Martin , Lisa Horvath , Hayley Thomas , Danka Sinikovic Zebic , Felicia Roncolato , Tee Lim , Chakiath Jose , Jarad Martin , Hans T. Chung , Annie Ebacher , Scott C. Morgan , Simon Hughes , Sean Matthew McBride , Paul J. Kelly , Ian D. Davis , Christopher Sweeney

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02446444 & NCT04136353

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 328)

DOI

10.1200/JCO.2024.42.4_suppl.328

Abstract #

328

Poster Bd #

N19

Abstract Disclosures

Similar Posters

First Author: Scott Williams

First Author: Scott G. Williams

First Author: Scott G. Williams

First Author: Junlong Zhuang